|
![](https://blogger.googleusercontent.com/img/proxy/AVvXsEhl79ZOZ6rbK9-VVrG-6IDI1kvvgpKiGc_2pIeTTdDrO-t7dZn3WwaFR0dD9vIGI2WWS2_UAgnK3ntxHdJntKXwlRmywZb9YE0oQDGHgieFYUhUv3oY7-qB3al99uDTEdkle5lWytrGWcL3Y56s_fouaqv9k0RGqZ7gXOcSHOMjWj9lOteh-mjUt39bxpBgmk3li4xDkJSOt2ecd3X8G5tQ427RHxWA=s0-d-e1-ft) |
Last week, the U.S. Food and Drug Administration approved Inbrija, an inhaled levodopa powder, for "off" episodes. The Michael J. Fox Foundation (MJFF) supported early clinical trials of the treatment, and this is the first regulatory approval of a Parkinson's therapy directly funded by us. |
Read More > |
|
|
|
|
2018 in Review, 2019 in Focus |
MJFF reflects on the past year of transformation in Parkinson's research and drug development, and plans to embrace new challenges in 2019. Read more about how our varied approaches to speed a cure for Parkinson's are paying off. |
Download the Booklet > |
|
|
|
|
|
With You We Can, Together We Will |
Our portfolio is bursting with promising strategies to treat Parkinson's symptoms, as well as therapies that may slow, stop or prevent the disease. Your year-end gift today will give more worthy ideas a chance tomorrow. |
Donate Now > |
|
|
|
|
|
|
|
|
|
|
|
|
No hay comentarios:
Publicar un comentario